CO HB1116

Creates a 17-member plant-based medicine policy review panel within the State Department to study the use of plant-based medicines to support mental health, with members appointed by the Governor and legislative leaders by August 1, 2022.

Panel membership includes representatives from physicians, pharmacists, alternative medicine providers, veterans, First Nations people, law enforcement, criminal defense attorneys, and other stakeholders with expertise in plant-based medicines.

Defines "plant-based medicine" as naturally occurring hallucinogenic plant-based compounds limited to psilocybin, psilocyn, dimethyltryptamine (DMT), and ibogaine.

Panel must study controlled substance reclassification, decriminalization, dosage determinations, safety protocols, regulation of medical use, and employment impacts, with the first meeting no later than October 1, 2022, and final report due January 1, 2024.

Panel automatically repeals on July 1, 2025, and must submit findings and policy recommendations to the House and Senate health committees, Governor, and Department of Human Services.